Peter J. O'Dwyer, MD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858
Penn Medicine Provider

About me

  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

My education and training

  • Residency: Saint Patrick's Hospital and Health Sciences Center
  • Residency: Hammersmith Hospital
  • Residency: Waterbury Hospital
  • Residency: Greater Baltimore Medical Center
  • Fellowship: University of Maryland Medical Center
  • Fellowship: National Cancer Institute

Spoken languages

English
English

Reviews

Average Rating

75 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
excellent and completely thorough
Anonymous
March 2026
great service
Anonymous
February 2026
please continue to provide great customer service and care. when the client is treated with respect, kindness and compassion it means a lot
Anonymous
January 2026
extremely skillful doctor who communicates clearly, honestly, and with great care.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. O'Dwyer is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL Comparison between the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur plus oral leucovorin regimen in Japanese and American patients with advanced colorectal cancer: joint USA and Japan study of UFT/LV , : 2003

Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy , Cancer Chemother Pharmacol: 2003

Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors , : 2003

Yao KS, O’Dwyer PJ Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention , Biochem Pharmacol: 2003

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI Gene expression patterns in epithelial ovarian carcinomas , : 2003

Flaherty KT, O'Dwyer PJ Phase II trials in oncology , Anticancer Drug Development Guide: 2003

Vasilevskaya I, O’Dwyer PJ Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy , Drug Resistance Updates: 2003

O’Dwyer PJ, Johnson SW Current status of oxaliplatin in colorectal cancer , Semin Oncol, 30(3 Supp 6): 2003,78-87

Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies , : 2003

Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer , : 2003